Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
ORIC Stock Chart & Stats
$10.42
-$0.67(-7.21%)
At close: 4:00 PM EST
$10.42
-$0.67(-7.21%)
Day’s Range― - ―
52-Week Range$3.90 - $14.93
Previous CloseN/A
Volume181.02K
Average Volume (3M)1.60M
Market Cap
$1.01B
Enterprise Value$968.43M
Total Cash (Recent Filing)$287.14M
Total Debt (Recent Filing)$3.30M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 24, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding97,389,280
10 Day Avg. Volume1,698,382
30 Day Avg. Volume1,603,125
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-4.94
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.19K
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$20.10Price Target Upside92.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CNS Activity And Clinical DifferentiationEnozertinib's brain‑penetrant design and observed complete intracranial tumor responses in certain patients could differentiate the program for treating EGFR‑mutated lung cancer with active brain metastases.
Dose Optimization And Pivotal DevelopmentDose‑optimization readouts for ORIC‑944 combined with established androgen‑receptor inhibitors could enable initiation of a pivotal Phase 3 trial in metastatic castration‑resistant prostate cancer, creating a clear late‑stage regulatory development path.
Early Efficacy And Analyst MomentumPromising early systemic responses in select EGFR patient groups, together with analyst model upgrades and an increased price target, suggest meaningful upside potential if larger trials confirm results.
Bears Say
Competitive Landscape RiskStrong competition from multiple EGFR inhibitors in late‑stage development raises the bar for regulatory approval and could meaningfully constrain future market share for enozertinib.
Narrowed Commercial OpportunityDiscontinuation of development in HER2 exon 20 mutated lung cancer reduces the addressable patient population and narrows the program's commercial opportunity.
Safety And Durability UncertaintyA portion of early responses remain unconfirmed and notable dose reductions were required for some patients, creating uncertainty about the durability of benefit and tolerability in broader populations.
Oric Pharmaceuticals News
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $3.90 and its highest was $14.93 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Oric Pharmaceuticals’s market cap is $1.01B.
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is Mar 24, 2026 which is in 43 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.075.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 97,389,280 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went up 0.492%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Currently, no hedge funds are holding shares in ORIC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oric Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.10 (92.90% Upside)
$20.10 (92.90% Upside)
Blogger Sentiment
Neutral
ORIC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 25.9%
Last 30 Days ▲ 25.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.90%
12-Months-Change
Fundamentals
Return on Equity
-39.73%
Trailing 12-Months
Asset Growth
42.75%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Stock 12 Month Forecast
Average Price Target
$20.10
▲(92.90% Upside)
Technical Analysis
Spyre Therapeutics
―
Trevi Therapeutics
―
Praxis Precision Medicines
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
Currently, No data available
---